These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28342632)

  • 1. The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis.
    Kim JS; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W; Jeong KH
    Int J Cardiol; 2017 Jul; 238():110-116. PubMed ID: 28342632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
    Jeong KH; Cho JH; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W
    Am J Kidney Dis; 2015 Jun; 65(6):916-24. PubMed ID: 25622774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
    Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
    Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
    Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
    Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
    Wang H; Qi J; Li Y; Tang Y; Li C; Li J; Han Y
    Br J Clin Pharmacol; 2018 Jan; 84(1):88-96. PubMed ID: 28921624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
    Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
    J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
    Butler K; Teng R
    Br J Clin Pharmacol; 2010 Jul; 70(1):65-77. PubMed ID: 20642549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
    Clavijo LC; Maya J; Carlson G; Angiolillo DJ; Teng R; Caplan R; Price MJ
    Cardiovasc Revasc Med; 2015 Dec; 16(8):450-4. PubMed ID: 26440227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
    Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
    Storey RF; Bliden KP; Ecob R; Karunakaran A; Butler K; Wei C; Tantry U; Gurbel PA
    J Thromb Haemost; 2011 Sep; 9(9):1730-7. PubMed ID: 21707911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
    Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
    Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.
    Jeong YH; Bliden KP; Antonino MJ; Park KS; Tantry US; Gurbel PA
    Am Heart J; 2012 Jul; 164(1):35-42. PubMed ID: 22795280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
    Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
    Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.
    Xin YG; Zhang HS; Li YZ; Guan QG; Guo L; Gao Y; Yu HJ; Zhang XG; Xu F; Zhang YL; Jia DL; Sun YX; Qi GX; Tian W
    Int J Cardiol; 2017 Feb; 228():275-279. PubMed ID: 27865197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.